文献速递炎症性肠病

MORF-057口服α4β7整合素抑制剂治疗中重度活动性溃疡性结肠炎的2期研究

A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-06

这项开放标签、2a期、单臂、多中心试验评估了口服MORF-057在中重度活动性UC患者中的疗效、药代动力学、药效学、安全性和耐受性。35例入组参与者中18例接受100mg每日两次口服治疗;第12周RHI评分平均变化为-6.4(SD 11.2),22.9%(8/35)达到RHI缓解(评分≤3),未观察到治疗出现的严重不良事件。

要点

  • 口服MORF-057耐受性良好,未观察到治疗出现的严重不良事件
  • 第12周RHI评分较基线平均下降6.4(SD 11.2)
  • 22.9%(8/35)参与者第12周达到RHI缓解(评分≤3)

核心结论

  • 口服MORF-057在中重度活动性UC中耐受性良好,并显示出有前景的疗效。

研究设计与样本

  • 开放标签、2a期、单臂、多中心试验,包含6周筛选期、52周治疗期(12周诱导+40周维持)和4周安全性随访。
  • 35例入组主队列,其中18例接受100mg口服MORF-057每日两次治疗整个治疗期。
  • 主要疗效终点为基线至第12周Robarts组织病理学指数(RHI)评分变化,在所有有可评估数据的参与者中评估。

主要发现

  • MORF-057耐受性良好,未观察到治疗出现的严重不良事件。
  • 第12周35例参与者RHI评分较基线平均变化为-6.4(标准差11.2)。
  • 22.9%(8/35)参与者达到RHI缓解(RHI评分≤3)。
  • 在有可评估数据的18例参与者中,MORF-057对药代动力学、药效学和临床疗效的影响在第12周达到,并持续至第52周保持一致。

关键数值与推荐

  • 主要疗效终点:基线至第12周RHI评分变化。
  • RHI缓解定义为RHI评分≤3。
  • 给药方案:100mg口服MORF-057每日两次。

临床怎么用

  • 口服小分子α4β7整合素抑制剂可能为中重度活动性UC提供新的治疗选择。
  • 治疗12周时可评估组织病理学改善和RHI缓解。

局限性

  • 开放标签、单臂设计,无对照组。
  • 主队列35例中仅18例接受100mg每日两次治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: MORF-057 is an orally administered small-molecule drug that inhibits α4β7 integrin-mediated recruitment of α4β7-expressing lymphocytes to the gut, a process implicated in the pathology of ulcerative colitis (UC). This study evaluated the efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability of MORF-057 in participants with moderately to severely active UC. METHODS: This open-label, phase 2a, single-arm, multicenter trial comprised a 6-week screening period, a 52-week active treatment period (including a 12-week induction period and 40-week maintenance period), and a 4-week safety follow-up period. Of the 35 participants enrolled in the main cohort, 18 participants received 100 mg of oral MORF-057 twice daily for the entire treatment period. The primary efficacy endpoint was a change in the Robarts Histopathology Index (RHI) score from baseline to week 12 and was assessed in all participants with evaluable data. Additional clinical, endoscopic, and histological variables were assessed at screening and at weeks 12 and 52. RESULTS: MORF-057 was well tolerated, and no treatment-emergent serious adverse events were observed. At week 12, participants (n = 35) exhibited a mean change from baseline in RHI score of -6.4 (standard deviation, 11.2). Additionally, 22.9% of participants (8/35) achieved RHI remission (RHI score ≤3). In participants with evaluable data (n = 18), the effects of MORF-057 on pharmacokinetics, pharmacodynamics, and clinical efficacy were achieved at week 12 and remained consistent to week 52. CONCLUSIONS: Overall, this study demonstrated that oral MORF-057 is well tolerated, with promising efficacy for individuals with moderately to severely active UC. CLINICALTRIALS: gov, Number: NCT05291689.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Sands BE, Schreiber S, Danese S, et al. A Phase 2 Study of MORF-057, an Oral α4β7 Integrin Inhibitor in Moderately to Severely Active Ulcerative Colitis. Clin Gastroenterol Hepatol. 2025. PMID: 40769468. doi:10.1016/j.cgh.2025.07.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。